MorphoSys (ETR:MOR) has been assigned a €98.00 ($120.99) price objective by equities research analysts at Commerzbank in a note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Commerzbank’s price objective would suggest a potential upside of 13.56% from the stock’s current price.
Other equities analysts have also issued research reports about the company. Oddo Bhf set a €90.00 ($111.11) price target on MorphoSys and gave the company a “buy” rating in a research note on Tuesday, February 20th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a price target on shares of MorphoSys in a research note on Tuesday, March 13th. Deutsche Bank set a €94.00 ($116.05) price target on MorphoSys and gave the company a “buy” rating in a research note on Monday, March 12th. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the company a “buy” rating in a research note on Thursday, December 7th. Finally, Independent Research set a €93.00 ($114.81) price target on MorphoSys and gave the company a “buy” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. MorphoSys currently has an average rating of “Hold” and an average target price of €84.02 ($103.73).
MorphoSys stock opened at €86.30 ($106.54) on Monday. MorphoSys has a one year low of €49.63 ($61.27) and a one year high of €88.10 ($108.77). The company has a market capitalization of $2,490.00 and a price-to-earnings ratio of -35.81.
TRADEMARK VIOLATION NOTICE: “MorphoSys (MOR) PT Set at €98.00 by Commerzbank” was first published by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.thestockobserver.com/2018/03/21/morphosys-mor-pt-set-at-98-00-by-commerzbank-2.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.